Sarepta Therapeutics Stock Filter Stocks by Fundamentals
| SRPT Stock | USD 126.66 2.14 1.66% |
Sarepta Therapeutics fundamentals help investors to digest information that contributes to Sarepta Therapeutics' financial success or failures. It also enables traders to predict the movement of Sarepta Stock. The fundamental analysis module provides a way to measure Sarepta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sarepta Therapeutics stock.
Sarepta | Shares Owned by Institutions |
Sarepta Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Sarepta Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sarepta Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sarepta Therapeutics' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.4 M | Jpmorgan Chase & Co | 2023-12-31 | 1.3 M | Citadel Advisors Llc | 2023-09-30 | 1.2 M | Bank Of America Corp | 2023-12-31 | 1.2 M | Farallon Capital Management, L.l.c. | 2023-12-31 | 1.2 M | Pictet Asset Manangement Sa | 2023-12-31 | 1.1 M | Casdin Capital, Llc | 2023-12-31 | 1 M | Norges Bank | 2023-12-31 | 836.8 K | Vanguard Group Inc | 2023-12-31 | 8.8 M | Blackrock Inc | 2023-12-31 | 6.2 M |
Sarepta Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.0524 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 11.81 B | ||||
| Shares Outstanding | 94.51 M | ||||
| Shares Owned By Insiders | 4.39 % | ||||
| Shares Owned By Institutions | 86.90 % | ||||
| Number Of Shares Shorted | 4.87 M | ||||
| Price To Earning | (20.43) X | ||||
| Price To Book | 13.43 X | ||||
| Price To Sales | 9.28 X | ||||
| Revenue | 1.24 B | ||||
| Gross Profit | (78.07 M) | ||||
| EBITDA | (267.82 M) | ||||
| Net Income | (535.98 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 23.61 X | ||||
| Total Debt | 1.4 B | ||||
| Debt To Equity | 3.72 % | ||||
| Current Ratio | 4.36 X | ||||
| Book Value Per Share | 9.17 X | ||||
| Cash Flow From Operations | (500.99 M) | ||||
| Short Ratio | 7.68 X | ||||
| Earnings Per Share | (5.80) X | ||||
| Price To Earnings To Growth | 159.25 X | ||||
| Target Price | 165.89 | ||||
| Number Of Employees | 1.31 K | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 12.15 B | ||||
| Total Asset | 3.26 B | ||||
| Retained Earnings | (4.45 B) | ||||
| Working Capital | 1.93 B | ||||
| Current Asset | 434.74 M | ||||
| Current Liabilities | 64.93 M | ||||
| Net Asset | 3.26 B |
About Sarepta Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sarepta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sarepta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sarepta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Sarepta Therapeutics Investors Sentiment
The influence of Sarepta Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Sarepta. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Sarepta Therapeutics' public news can be used to forecast risks associated with an investment in Sarepta. The trend in average sentiment can be used to explain how an investor holding Sarepta can time the market purely based on public headlines and social activities around Sarepta Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sarepta Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sarepta Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Sarepta Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Sarepta Therapeutics.
Sarepta Therapeutics Implied Volatility | 147.43 |
Sarepta Therapeutics' implied volatility exposes the market's sentiment of Sarepta Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Sarepta Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Sarepta Therapeutics stock will not fluctuate a lot when Sarepta Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sarepta Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sarepta Therapeutics' short interest history, or implied volatility extrapolated from Sarepta Therapeutics options trading.
Currently Active Assets on Macroaxis
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock:Check out Sarepta Therapeutics Piotroski F Score and Sarepta Therapeutics Altman Z Score analysis. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.80) | Revenue Per Share 13.456 | Quarterly Revenue Growth 0.535 | Return On Assets (0.05) | Return On Equity (0.86) |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.